TWI754817B - 以人工混雜ｔ輔助細胞抗原決定位以有限度的ｔ細胞發炎反應促進目標抗體的生產 - Google Patents

以人工混雜ｔ輔助細胞抗原決定位以有限度的ｔ細胞發炎反應促進目標抗體的生產 Download PDF

Info

Publication number
TWI754817B
TWI754817B TW108115540A TW108115540A TWI754817B TW I754817 B TWI754817 B TW I754817B TW 108115540 A TW108115540 A TW 108115540A TW 108115540 A TW108115540 A TW 108115540A TW I754817 B TWI754817 B TW I754817B
Authority
TW
Taiwan
Prior art keywords
peptide
epitope
epitopes
antigenic site
cell
Prior art date
Application number
TW108115540A
Other languages
English (en)
Chinese (zh)
Other versions
TW201946649A (zh
Inventor
長怡 王
Original Assignee
美商聯合生物醫學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商聯合生物醫學公司 filed Critical 美商聯合生物醫學公司
Publication of TW201946649A publication Critical patent/TW201946649A/zh
Application granted granted Critical
Publication of TWI754817B publication Critical patent/TWI754817B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW108115540A 2018-05-04 2019-05-06 以人工混雜ｔ輔助細胞抗原決定位以有限度的ｔ細胞發炎反應促進目標抗體的生產 TWI754817B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862667123P 2018-05-04 2018-05-04
US62/667,123 2018-05-04

Publications (2)

Publication Number Publication Date
TW201946649A TW201946649A (zh) 2019-12-16
TWI754817B true TWI754817B (zh) 2022-02-11

Family

ID=68386088

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108115540A TWI754817B (zh) 2018-05-04 2019-05-06 以人工混雜ｔ輔助細胞抗原決定位以有限度的ｔ細胞發炎反應促進目標抗體的生產

Country Status (12)

Country Link
US (2) US20220023400A1 (https=)
EP (1) EP3790581A4 (https=)
JP (2) JP2021523127A (https=)
KR (1) KR20210010873A (https=)
CN (1) CN112218655A (https=)
AU (1) AU2019262609A1 (https=)
BR (1) BR112020022443A2 (https=)
CA (1) CA3099296A1 (https=)
MX (1) MX2020011733A (https=)
SG (1) SG11202010942WA (https=)
TW (1) TWI754817B (https=)
WO (1) WO2019213555A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020240332A1 (ja) * 2019-05-31 2020-12-03 株式会社半導体エネルギー研究所 半導体装置の作製方法
CN112876570B (zh) * 2021-02-09 2022-07-26 中国农业科学院生物技术研究所 非洲猪瘟病毒疫苗及其制备方法
KR20250040007A (ko) * 2022-07-14 2025-03-21 백시니티, 인크. Tau 펩타이드 면역원 작제물
CN118812726B (zh) * 2024-06-26 2025-05-16 西北民族大学 脑心肌炎多抗原表位重组蛋白及其在制备脑心肌炎疫苗中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280733A1 (en) * 2002-09-12 2006-12-14 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
US20110070255A1 (en) * 2001-05-25 2011-03-24 United Biomedical, Inc. Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
US20140008020A1 (en) * 2012-07-02 2014-01-09 Tokyo Electron Limited Plasma processing apparatus and temperature control method
US20150374816A1 (en) * 2013-02-18 2015-12-31 Spring Bank Pharmaceuticals, Inc. Design of short oligonucleotides as vaccine adjuvants and therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
US20140088020A1 (en) * 1999-08-30 2014-03-27 David S Terman Composition and Methods for Treatment of Cancer
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US10450352B2 (en) * 2016-03-23 2019-10-22 Board Of Regents, The University Of Texas System Engineered polypeptides for antigen delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070255A1 (en) * 2001-05-25 2011-03-24 United Biomedical, Inc. Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
US20060280733A1 (en) * 2002-09-12 2006-12-14 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
US20140008020A1 (en) * 2012-07-02 2014-01-09 Tokyo Electron Limited Plasma processing apparatus and temperature control method
US20150374816A1 (en) * 2013-02-18 2015-12-31 Spring Bank Pharmaceuticals, Inc. Design of short oligonucleotides as vaccine adjuvants and therapeutic agents

Also Published As

Publication number Publication date
AU2019262609A1 (en) 2020-12-03
CN112218655A (zh) 2021-01-12
WO2019213555A1 (en) 2019-11-07
SG11202010942WA (en) 2020-12-30
US20220023400A1 (en) 2022-01-27
BR112020022443A2 (pt) 2021-02-09
CA3099296A1 (en) 2019-11-07
JP2021523127A (ja) 2021-09-02
US20250262286A1 (en) 2025-08-21
EP3790581A4 (en) 2022-06-22
MX2020011733A (es) 2021-01-15
KR20210010873A (ko) 2021-01-28
EP3790581A1 (en) 2021-03-17
JP2024095743A (ja) 2024-07-10
TW201946649A (zh) 2019-12-16

Similar Documents

Publication Publication Date Title
JP7555598B2 (ja) 合成ペプチド免疫原のための免疫刺激薬としての人工無差別ｔヘルパー細胞エピトープ
US20250262286A1 (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
AU764961B2 (en) Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
CN113574073B (zh) 针对降钙素基因相关肽(cgrp)的肽免疫原及其用于预防和治疗偏头痛的制剂
AU2016201589A1 (en) Peptide adjuvants
TWI823051B (zh) 針對垂體腺苷酸環化酶激活胜肽的胜肽免疫原及其預防和治療偏頭痛的製劑
HK40045220A (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
TW202142551A (zh) 針對pcsk9胜肽免疫原及其預防和治療pcsk9介導疾病的製劑
RU2839585C2 (ru) Искусственные неизбирательные эпитопы клеток т-хелперов как иммунные стимуляторы для синтетических пептидных иммуногенов
TW202028223A (zh) 針對源自c9orf72二肽重複蛋白的胜肽免疫原結構
TW201930346A (zh) 用於ＩｇＥ介導過敏性疾病治療之靶向膜鑲嵌型ＩｇＥ的胜肽免疫原及其劑型
EP4554618A2 (en) Tau peptide immunogen constructs
HK40049481A (en) Peptide immunogen constructs directed against dipeptide repeat proteins from c9orf72